We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast

Ifat Zerin Krase, PharmD1; Kevin Cavanaugh, MD2; Clara Curiel-Lewandrowski, MD2
[+] Author Affiliations
1University of Arizona College of Medicine, Tucson
2Department of Dermatology, University of Arizona, Tucson
JAMA Dermatol. 2016;152(3):348-350. doi:10.1001/jamadermatol.2015.3405.
Text Size: A A A
Published online


This case report describes successful treatment of refractory pityriasis rubra pilaris with the novel phosphodiesterase 4 inhibitor apremilast.

Pityriasis rubra pilaris (PRP) is an inflammatory dermatologic disorder of unknown cause characterized by hyperkeratotic follicular papules combining into salmon-colored scaling plaques, palmoplantar hyperkeratosis, and sharply demarcated islands of spared skin.1 We report a case of refractory PRP treated with the immune modulator apremilast.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
A Case of Refractory Pityriasis Rubra Pilaris Before and After 8 Months of Apremilast Therapy

Almost complete resolution is seen on the back of this elderly male patient.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections